Octave bioscience4/7/2023 Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. In developing its care management platform, Octave Bioscience is integrating novel measurement tools with structured analytical data models, ensuring that the precision care solution for physicians and their patients is complementary to the corresponding care solution for pharmaceutical companies developing groundbreaking technologies, payers, and population health on a larger scale.įor more information, please visit and About the Octave Bioscience Comprehensive Care Platform This investment underscores industry interest in addressing the unmet needs of those living with, treating, and researching MS. "We look forward to working with the team as they continue to craft their platform focused on multi-modality, integrated findings and expanded disease insights." Rubin, Ph.D., Managing Director of Merck GHIF. "Octave’s approach to improve patient outcomes in multiple sclerosis is powerful and we believe will have broader neurodegenerative disease applications," said David M. We believe that this is just the beginning of a long and productive relationship that can help us shift the paradigm for patients with MS and a broad range of neurodegenerative diseases." "This investment further expands our already broad syndicate and further enables the full breadth of Octave’s services, ranging from measurement and management tools for physicians as they manage their patients to a precision-based set of tools and services that can help pharmaceutical companies better characterize their therapies and reveal additional insight to optimize their pipeline programs. "The investment from Merck GHIF is a testament to the strength of our strategy, our team, technologies and platform," said William Hagstrom, Chief Executive Officer and Founder of Octave. This brings Octave Bioscience’s total funding to $46M to date.Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases. The company raised $32M in Series B round on Dec 17, 2020. Octave Bioscience is backed by Northpond Ventures, Deerfield Management, Casdin Capital, BlueCross BlueShield Venture Partners, Echo Health Ventures, Section 32 and others. Octave Bioscience's novel measurement tools feed into care pathway models and analytical support systems designed to improve patient management decisions, generate better outcomes and lower costs. Octave Bioscience's platform includes tracking of blood based biomarkers, enhanced MRI insights and patient monitoring using mobile tools, sensors and a nurse led care partner program. Octave Bioscience’s Comprehensive Care Platform provides a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. ![]() The company is headquartered in Menlo Park, California. Octave Bioscience was co-founded in 2013 by Melinda Thomas and William Hagstrom. Octave Bioscience aims to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases. Octave Bioscience is the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |